Multiple myeloma · 14 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pomalidomide, Dexamethasone, Pembrolizumab Variant #01 | — | R 193 014 | 28d | — | — | ~26 | ~R 5 018 368 indirect | — |
Bortezomib monotherapy Variant #03 | — | R 6 762 | 21d | ~30.3 mo | — | ~8 | ~R 54 096 PFS proxy · indirect | 5 |
VAD and Cyclosporine Variant #01 | — | R 4 616 | 28d | — | — | ~4 | ~R 15 685 indirect | — |
VAD Variant #02 | — | R 2 493 | 28d | — | — | ~4 | ~R 7 193 indirect | — |
DECA Variant #01 | — | R 1 863 | 21d | — | — | ~2 | ~R 3 727 indirect | — |
Cyclophosphamide monotherapy Variant #01 | — | R 1 680 | 28d | — | ~15.8 mo | ~1 | ~R 1 680 PFS proxy · indirect | 1 |
Dexamethasone monotherapy Variant #03 | — | R 1 215 | 28d | — | — | ~4 | ~R 4 861 indirect | — |
Carmustine and Doxorubicin Variant #01 Partial | — | R 338 | 28d | — | — | ~2 | ~R 676 indirect | — |
Placebo Partial | — | — | — | ~22.2 mo | — | — | — | 2 |
EDAP Partial | — | — | — | — | — | — | — | — |
Stilbamidine and Urethane Partial | — | — | — | — | — | — | — | — |
Belantamab mafodotin monotherapy Variant #01 Partial | — | — | 21d | ~11.2 mo | — | ~2 | — | 1 |
Tisagenlecleucel monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
Urethane monotherapy Partial | — | — | — | — | — | — | — | — |
14 of 14 regimens shown